Nizatidine, a new H 2 -receptor antagonist, inhibits acetylcholinesterase (AChE) activity 1 and oral nizatidine has been reported to be an effective protective agent against acid aspiration syndrome 2, 3 . In this study we sought to determine how nizatidine affects the neuromuscular blocking actions of vecuronium. We also reevaluated the previously described 2 effects of nizatidine on gastric volume and pH, using 300 mg (a larger dose) given two hours preoperatively.
MATERIALS AND METHODS
With the approval of our institutional ethics committee and written informed consent of the patients, a prospective study of 20 patients scheduled to undergo elective orthopaedic, plastic or ear nose and throat surgery was undertaken. All patients were of ASA physical status 1 or 2 and ranged from 18 to 67 years of age. Patients with gastrointestinal, neurological or neuromuscular disease and patients who received medications known to affect gastric fluid composition or gastric emptying were excluded. The patients, who were fasted overnight (at least 10 hours) and received no other premedication, were allocated randomly (n=10 for each group) to either a control group or the nizatidine group.
The study medication was given orally two hours preoperatively with 50 ml of water. The control group received a cornstarch placebo. The nizatidine group received nizatidine 300 mg. A size 16Fr nasogastric tube was inserted and its position confirmed by auscultation of injected air. Before induction of anaesthesia, gastric contents were aspirated with the patient in the supine and then in the right and left lateral decubitus positions 4 and the volume and pH were measured.
Anaesthesia was induced with thiopentone 5 mg/kg and 1.5% isoflurane in 98.5% oxygen followed by vecuronium 0.1 mg/kg. The neuromuscular block was assessed with a Datex Relaxograph 5 (Datex Ohmeda, Helsinki, Finland), which measured adductor pollicis electromyography (EMG) in response to supramaximal stimulation of the ulnar nerve. For the EMG recording, the stimulating current was delivered through surface electrodes placed on the wrist, and consisted of train-of-four (TOF) stimuli with a pulse width of 100 µs and a frequency of 2 Hz every 10 s. Automatic calibration and baseline recordings were performed immediately after induction of anaesthesia with thiopentone. Isoflurane and vecuronium were not given until the control EMG response was obtained. The first twitch height (T1) was measured from the first response in the TOF. The following variables of neuromuscular function were obtained from twitch recording: onset time (the time from injection of vecuronium to maximal effect or T1=0) and duration time 25 (the time from injection until recovery of 25% of baseline twitch amplitude). Tracheal intubation was performed when T1 was <10%. After intubation, the lungs were mechanically ventilated using a semi-closed circle system (Ohmeda Modulus ® CD Anesthesia System, Ohmeda) with isoflurane 1.5% in a 1:1 mixture of nitrous oxide and oxygen at 6 l/min. Ventilation was set at 8 breaths per minute, with a tidal volume of 8 ml/kg, and an inspiratory:expiratory ratio of 1:2.
Comparison of patient demographic data such as age, weight, height and onset and recovery characteristics were made using an unpaired t-test and the chi-square test was used for patient gender. Gastric fluid volume and pH were also compared using the unpaired t-test. Fisher's exact probability test was used for proportions of patients at risk of developing pulmonary acid aspiration syndrome. P<0.05 was considered statistically significant.
RESULTS
There were no significant differences between the two groups in gender, age, weight or height (Table 1) .
There were no significant differences between the two groups in onset time or duration time 25 (Table 2) .
Gastric fluid volume was greater in the control group than in the nizatidine group (P<0.005) and gastric pH was lower in the control group than in the nizatidine group (P<0.0001) ( Table 3) .
Using a gastric pH <2.5 and volume >25 ml as the criteria for patients at risk of developing Mendelson's syndrome, there were seven (70%) in the control group and none (0%) in the nizatidine group (P<0.005).
None of the patients showed clinical evidence of regurgitation or aspiration. None of the patients had particulate matter in gastric aspirates. There were no adverse effects considered related to nizatidine. DISCUSSION Some H 2 -antagonists, including nizatidine, have been reported to inhibit AChE activity 1, 6, 7 . We did not find any significant effect of nizatidine on the onset time or duration time 25 of vecuronium. Our study lacked power to state with confidence that there was no difference in the neuromuscular blocking effects. It is possible that a larger study may demonstrate a statistical difference, particularly in the duration time 25. However, inspection of our results (approximately a 10% difference in means and a 20% standard deviation for the duration time 25) suggests a clinically significant effect is unlikely to emerge from a larger study. Our results are similar to the results of Eisenkraft et al 8 who showed no difference in sensitivity to vecuronium between those myasthenic patients who received pyridostigmine preoperatively and those who did not.
In 1946, Mendelson 9 described an acid aspiration syndrome in obstetric patients and suggested the 47 NIZATIDINE AND VECURONIUM Mean±SD are given for each value. No significant differences were found between the two groups. Mean±SD are given for each value. No significant differences were found between the two groups. possible benefit of using antacid drugs as a prophylactic measure. Factors which influence the severity of the aspiration syndrome include the pH and volume of gastric contents. Criteria commonly used to define patients "at risk" of developing Mendelson's syndrome include a gastric content pH <2.5 and volume >25 ml (0.4 ml/kg) 10, 11 , although the validity of these criteria has been questioned. H 2 -blockers administered before an operation have been used to reduce the acidity and volume of the gastric contents and thus to prevent the aspiration syndrome 2 . Oral nizatidine has been reported to be an effective protective agent against acid aspiration syndrome in adults 2 and children 3 , and we reevaluated its effect in this study. Popat et al 2 gave oral nizatidine 150 mg (half our dose) to their patients at least 45 minutes (mean: 92, range: 45-147 min) before induction of anaesthesia. Of these patients, 13.3% had gastric content pH <2.5 and neither had volume >25 ml. They noted that none of the patients who received nizatidine (or ranitidine, which was also examined in that study) more than 90 minutes preoperatively had gastric content pH <2.5. This suggested a latent period was required before the gastric pH increased. In the light of these results we administered nizatidine two hours before the patient's arrival in the operating room.
In summary, the results of this study indicate that oral nizatidine 300 mg, a new H 2 -receptor antagonist which has anti-acetylcholinesterase (anti-AChE) activity, does not significantly influence the neuromuscular blocking effects of vecuronium. All patients receiving nizatidine two hours before anaesthesia induction had a gastric content pH greater than 2.5 and a volume of less than 25 ml, suggesting this protocol may be useful for prophylaxis against acid aspiration syndrome.
